Advancing Science. Improving Connections.

Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.

Our Patients

Focusing on the unmet medical needs of patients with rare disorders and their families

More

Our Company

Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases

More

Our Pipeline

Pioneering cannabinoid treatments for neuropsychiatric conditions

More

Latest News

11.22

Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for Zygel™

Read More
11.15

Zynerba Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Highlights

Read More
10.21

Zynerba Pharmaceuticals Announces Presentations at Two Upcoming Scientific Conferences in October

Read More
10.19

Zynerba Pharmaceuticals Announces Presentation of Poster at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit

Read More

This site uses cookies to give you a better browsing experience. By continuing to use this website, you accept our use of these cookies. For more information, see our Privacy Notice.